Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H18N8O |
| Molecular Weight | 254.2922 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=N)NCCCC[C@H](N)C(=O)NC1=NN=NN1
InChI
InChIKey=LGLHLXSNASPEAX-ZETCQYMHSA-N
InChI=1S/C9H18N8O/c1-6(10)12-5-3-2-4-7(11)8(18)13-9-14-16-17-15-9/h7H,2-5,11H2,1H3,(H2,10,12)(H2,13,14,15,16,17,18)/t7-/m0/s1
| Molecular Formula | C9H18N8O |
| Molecular Weight | 254.2922 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
L-N6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51 or L-NIL-TA) is rapidly converted in vivo to the active metabolite L-N6-(1-iminoethyl)lysine (L-NIL). L-NIL is a relatively selective inhibitor of nitric-oxide synthase type 2 (NOS2). Unlike L-NIL, L-NIL-TA has minimal inhibitory activity in vitro on human NOS2. However, it is rapidly converted in vivo to L-NIL and produces dose-dependent inhibition of iNOS in acute and chronic models of inflammation in the rodent with efficacy comparable to L-NIL. L-NIL-TA produces marked inhibition of exhaled breath NO in normal and asthmatic subjects without producing the side effects observed following the systemic administration of non-selective NOS inhibitors, and thus provides support for the potential use of iNOS inhibitors to treat a range of inflammatory clinical disorders.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Role of nitric oxide in chronic allergen-induced airway cell proliferation and inflammation. | 2003 Jan |
|
| A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. | 2003 Jul |
|
| Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. | 2003 Nov |
|
| Disposition and pharmacokinetics of L-N6-(1-iminoethyl)lysine-5-tetrazole-amide, a selective iNOS inhibitor, in rats. | 2004 May |
Sample Use Guides
In a randomized double-blind placebo-controlled crossover trial, SC-51 (L-NIL-TA) was administered as a single oral dose (20 or 200 mg) in separate cohorts of healthy volunteers and mild asthmatic patients.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:38:00 GMT 2023
by
admin
on
Sat Dec 16 11:38:00 GMT 2023
|
| Record UNII |
XZS3S55BTX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L-NIL-TA
Created by
admin on Sat Dec 16 11:38:00 GMT 2023 , Edited by admin on Sat Dec 16 11:38:00 GMT 2023
|
PRIMARY | Dec 14, 2015 <b>...</b> Updated results from the trial were presented at the <b>51</b>st Annual Meeting of ... However, aldesleukin (IV, <b>SC</b>) was withdrawn from the market in??... | ||
|
9881505
Created by
admin on Sat Dec 16 11:38:00 GMT 2023 , Edited by admin on Sat Dec 16 11:38:00 GMT 2023
|
PRIMARY | |||
|
XZS3S55BTX
Created by
admin on Sat Dec 16 11:38:00 GMT 2023 , Edited by admin on Sat Dec 16 11:38:00 GMT 2023
|
PRIMARY | |||
|
179337-79-2
Created by
admin on Sat Dec 16 11:38:00 GMT 2023 , Edited by admin on Sat Dec 16 11:38:00 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
